Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we ...

Pfizer reported positive phase 2 results for atirmociclib in metastatic breast cancer, adding a new oncology asset to its ...

Investors continued to be positive on the pharmaceutical giant following a deal reached with the government. Among other benefits, it will have a reprieve from potential tariffs on its industry. 10 ...

Pfizer (PFE) is back in focus after recent trading left the shares around $27.32, prompting investors to reassess the company’s value score of 3, revenue of $62.6b, and net income of $7.7b. See our ...

Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

They aren't just "pandemic stocks." ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...